(Q36788423)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

4

Teun van Gelder

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Brenda C M de Winter

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Ron A A Mathôt

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

English

0 references

publication date

1 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

251-261

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring?

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Immunosuppression: practice and trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Clinical pharmacokinetics of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Therapeutic drug monitoring of immunosuppressant drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Immunosuppression with mycophenolic acid: one size does not fit all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Individualization of mycophenolate mofetil dose in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Mycophenolate mofetil: how to further improve using an already successful drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Determinants of mycophenolic acid levels after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Population pharmacokinetics of mycophenolic acid in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

The effect of oral iron admiinistration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Therapeutic drug monitoring of mycophenolate mofetil in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.251

21 January 2018

Identifiers

DOI

10.1517/17425255.3.2.251

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428154%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference